News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Pfizer Disappointed Medsafe May Deny Arthritis Med

Pfizer New Zealand Says Doubt Over Future Health Of 60,000 Arthritis Patients

Pfizer New Zealand Ltd is disappointed with a preliminary recommendation by health officials that could deny 60,000 New Zealanders access to important arthritis medications.

Pfizer New Zealand received a letter from the Government agency, Medsafe, on Friday, announcing its preliminary intention to revoke marketing consent for the company’s COX-2 inhibitor arthritis medications, Celebrex, Dynastat and Bextra.

“It’s difficult to follow the thinking behind the preliminary recommendation which appears to be based on data from one uncompleted study investigating Celebrex in cancer prevention (the APC study),” Pfizer General Manager Mark Crotty said.

”This study's preliminary results showed an increase in cardiovascular events - but at doses of 400-800mg a day, which is well in excess of the dosage (200mg or less) that approximately 90 percent of New Zealanders are on.”

Rheumatologist from Queen Elizabeth Hospital, Rotorua, Dr John Petrie said he is astounded and deeply concerned with the proposed withdrawal of the COX-2s.

"These are important treatment options for all patients suffering the pain associated with Arthritis, in particular for those that are unable to take conventional NSAIDs due to gastro- intestinal side effects," he said.

"I believe that products like Celebrex are as safe as all other anti-inflammatory products available in New Zealand.

"Patients will be forced to move back to NSAIDs, a group of pain killers whose cardiovascular and gastro-intestinal safety has not been demonstrated to be superior to COX-2s."

Pfizer New Zealand said Medsafe's apparent intention to revoke the consent for Bextra, which is available in New Zealand for the treatment of the signs and symptoms of Osteoarthritis and Rheumatoid Arthritis, is inappropriate and not justified by the data.

Approximately 1500 patients take Bextra in New Zealand.

Medsafe is also seeking to revoke consent for Dynastat, a single-dose post-operative pain reliever only used in hospitals which may decrease the need for opioids

Pfizer NZ is providing further information to Medsafe to assist it in its evaluation of Pfizer’s arthritis medications.

Pfizer advises patients with any concerns to contact their doctor.

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
K Emma Ng's Old Asian, New Asian

This book, written by a young second-generation Chinese New Zealander, gives many examples of the racism that Asian New Zealanders experience. More>>